| Literature DB >> 33858477 |
Angelo Sabag1,2,3, Shelley E Keating4, Kimberley L Way5,6,7,8, Rachelle N Sultana5,6, Sean M Lanting9, Stephen M Twigg10, Nathan A Johnson5,6.
Abstract
BACKGROUND: Exercise-induced improvements in cardiorespiratory fitness (CRF) often coincide with improvements in insulin sensitivity and reductions in liver fat content. However, there are limited data concerning the relationship between CRF and liver fat content in adults with varying degrees of metabolic dysfunction.Entities:
Keywords: Exercise; Fatty liver; Obesity
Year: 2021 PMID: 33858477 PMCID: PMC8050897 DOI: 10.1186/s13102-021-00261-9
Source DB: PubMed Journal: BMC Sports Sci Med Rehabil ISSN: 2052-1847
Participant characteristics
| Normal Glucose Tolerance ( | Type 2 Diabetes ( | Total ( | ES (95%CI) | ||
|---|---|---|---|---|---|
| Gender (M/F) | 13/24 | 20/15 | 33/39 | 0.610 | |
| MAFLD (Y/N) | 16/21 | 23/12 | 39/33 | 0.056 | |
| Age (years) | 44.84 (10.23) | 53.97 (7.85) | 49.28 (10.18) | -1.030 (-3.93 to 1.86) | |
| Waist Circumference (cm) | 101.21 (12.30) | 116.30 (12.43) | 108.55 (14.43) | -1.26 (-5.18 to 2.67) | |
| BMI (kg/m2) | 33.62 (4.52) | 35.81 (5.04) | 34.69 (4.87) | 0.056 | -0.47 (-1.99 to 1.05) |
| LF (%) | 6.59 (5.93) | 10.25 (7.43) | 8.37 (6.90) | -0.65 (-0.84 to -0.45) | |
| SBP (mmHg) | 122.92 (14.41) | 129.41 (16.85) | 126.07 (15.87) | 0.083 | -0.43 (-5.40 to 4.55) |
| DBP (mmHg) | 79.30 (6.99) | 80.16 (9.28) | 79.71 (8.14) | 0.658 | -0.11 (-2.72 to 2.50) |
| AST (U/L) | 22.32 (9.17) | 29.06 (21.05) | 25.60 (16.32) | 0.080 | -0.43 (-5.58 to 4.73) |
| ALT (U/L) | 22.95 (10.13) | 35.17 (23.10) | 28.89 (18.59) | -0.71 (-6.37 to 4.95) | |
| CRP (mg/L) | 4.65 (4.71) | 4.11 (4.73) | 4.39 (4.70) | 0.628 | 0.12 (-1.38 to 1.62) |
| FBG (mmol/L) | 4.28 (0.61) | 8.21 (3.00) | 6.19 (2.90) | -1.87 (-2.56 to 1.18) | |
| aInsulin (mU/L) | 10.22 (5.96) | 12.17 (6.63) | 11.08 (6.29) | 0.212 | -0.32 (-2.32 to 1.68) |
| aHOMA-IR | 2.00 (1.34) | 4.43 (2.61) | 3.07 (2.33) | -1.21 (-1.86 to -0.55) | |
| Triglycerides (mmol/L) | 1.49 (0.86) | 1.66 (0.67) | 1.57 (0.78) | 0.368 | -0.23 (-0.47 to 0.02) |
| Total Cholesterol (mmol/L) | 5.59 (1.25) | 4.43 (0.80) | 5.03 (1.20) | 1.14 (0.80 to 1.47) | |
| HDL (mmol/L) | 1.40 (0.32) | 1.15 (0.26) | 1.28 (0.32) | 0.88 (0.79 to 0.98) | |
| LDL (mmol/L) | 3.53 (0.95) | 2.47 (0.75) | 3.02 (1.01) | 1.27 (1.00 to 1.55) | |
| FFA (umol/L) | 389.67 (162.24) | 508.71 (198.24) | 447.54 (189.09) | -0.68 (-58.18 to 56.83) | |
| VO2peak (mL/kg/min) | 22.24 (3.90) | 20.75 (3.51) | 21.52 (3.77) | 0.094 | 0.41 (-0.77 to 1.59) |
Data presented as mean (SD). ES effect size, CI confidence interval, M male, F female, MAFLD metabolic dysfunction-associated fatty liver disease, Y yes, N no, BMI body mass index, LF% liver fat percentage, SBP systolic blood pressure, DBP diastolic blood pressure, AST aspartate aminotransferase, ALT alanine aminotransferase, CRP high-sensitivity C-reactive protein, FBG fasting blood glucose, HOMA-IR homeostatic model assessment of insulin resistance, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, FFA free fatty acids, VO Peak oxygen consumption. aHOMA-IR and insulin measures reported for 37 participants with normal glucose tolerance and 29 participants with T2D as 6 participants with T2D were undergoing exogenous insulin therapy
Partial correlations between graded exercise test measured cardiorespiratory fitness, demographic, cardiometabolic and anthropometric variables
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| −.271* | ||||||||||||||||||
| .411** | −0.225 | |||||||||||||||||
| −0.173 | 0.233 | −0.156 | ||||||||||||||||
| −0.184 | .734** | −0.183 | 0.103 | |||||||||||||||
| −.527** | .403** | −.527** | 0.106 | .387** | ||||||||||||||
| −.490** | .547** | −.466** | .370** | .475** | .790** | |||||||||||||
| −0.199 | .423** | −0.168 | 0.163 | .311** | .268* | .366** | ||||||||||||
| −0.231 | .578** | −0.191 | .256* | .391** | .339** | .466** | .900** | |||||||||||
| −0.093 | .364** | −0.085 | 0.23 | 0.183 | 0.004 | 0.079 | .372** | .338** | ||||||||||
| 0.121 | −0.078 | 0.132 | −.492** | −0.032 | − 0.181 | −.293* | 0.042 | − 0.03 | 0.172 | |||||||||
| 0.079 | −0.082 | 0.114 | −.357** | −0.122 | − 0.065 | −0.229 | − 0.175 | −.237* | −0.216 | .518** | ||||||||
| 0.145 | −0.162 | −.433** | −.555** | −0.103 | − 0.17 | −.292* | −0.018 | − 0.082 | 0.055 | .945** | .417** | |||||||
| −.283* | .375** | −0.197 | .317** | .380** | 0.151 | .286* | .357** | .351** | .379** | 0.048 | 0.019 | −0.068 | ||||||
| −.344** | 0.16 | −.339** | 0.015 | 0.195 | .406** | .310** | .250* | .246* | 0.055 | −0.11 | −0.074 | −0.133 | − 0.002 | |||||
| −.259* | .268* | −.249* | .631** | 0.159 | 0.108 | .361** | 0.161 | 0.232 | .515** | −.245* | −0.185 | −.416** | .400** | 0.078 | ||||
| −.403** | .435** | .835** | .835** | .411** | .524** | .534** | −0.008 | 0.214 | 0.242 | −0.158 | − 0.09 | −0.263 | 0.177 | 0.18 | 0.177 | |||
| −.292* | 0.168 | −.281* | −0.021 | .332** | .272* | .395** | .278* | .287* | 0.038 | 0.056 | −0.103 | 0.023 | 0.233 | −0.014 | .238* | 0.212 | ||
| −0.133 | 0.198 | −0.118 | −0.114 | .257* | 0.226 | .247* | −0.102 | −0.087 | 0.052 | 0.151 | .293* | 0.031 | 0.067 | 0.017 | .244* | 0.2 | .618** |
* p < 0.05; ** p < 0.01
Data presented as correlation coefficient (r). CRF cardiorespiratory fitness, LF% liver fat percentage, T2D type 2 diabetes, MAFLD metabolic dysfunction-associated fatty liver disease, BMI body mass index, WC waist circumference, AST aspartate aminotransferase, ALT alanine aminotransferase, TG triglycerides, TC Total Cholesterol HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, FFA free fatty acids, CRP high-sensitivity C-reactive protein, SBP systolic blood pressure, DBP diastolic blood pressure
Participant characteristics when stratified by cardiorespiratory fitness
| Lowest Fitness, | IQR, | Highest Fitness, | Between group | ES (95%CI) | |
|---|---|---|---|---|---|
| Gender (M/F) | 8/10 | 17/19 | 8/10 | 0.974 | |
| Type 2 Diabetes (Y/N) | 11/7 | 18/18 | 6/12 | 0.250 | |
| MAFLD (Y/N) | 15/3 | 16/20 | 8/10 | ||
| Age (years) | 54.56 (9.94) | 47.33 (9.48) | 47.89 (10.47) | 0.67 (-2.57 to 3.91) | |
| Waist Circumference (cm) | 119.03 (15.38) | 107.39 (12.64) | 100.38 (10.70) | 1.45 (-2.76 to 5.65) | |
| BMI (kg/m2) | 39.81 (4.29) | 33.34 (3.55) | 32.27 (4.12) | 1.85 (0.51 to 3.18) | |
| LF (%) | 11.40 (6.25) | 8.00 (7.48) | 6.08 (5.40) | 0.94 (-0.92 to 2.79) | |
| SBP (mmHg) | 135.66 (20.17) | 124.77 (13.08) | 119.09 (11.86) | 1.03 (-4.22 to 6.28) | |
| DBP (mmHg) | 83.21 (11.33) | 78.60 (6.58) | 78.44 (6.46) | 0.107 | 0.53 (-2.40 to 3.46) |
| AST (U/L) | 30.39 (22.57) | 25.78 (16.16) | 20.44 (3.62) | 0.189 | 0.633 (-4.50 to 5.77) |
| ALT (U/L) | 34.72 (22.72) | 29.22 (18.81) | 22.39 (10.82) | 0.136 | 0.71 (-4.94 to 6.36) |
| CRP (mg/L) | 7.30 (6.72) | 3.38 (3.41) | 3.51 (3.30) | 0.74 (-0.94 to 2.42) | |
| FBG (mmol/L) | 7.14 (3.16) | 6.26 (3.14) | 5.01 (1.59) | 0.101 | 0.88 (0.08 to 1.67) |
| aInsulin (mU/L) | 14.29 (7.79) | 10.68 (6.16) | 8.72 (3.37) | 0.96 (-0.95 to 2.86) | |
| aHOMA-IR | 4.56 (2.89) | 2.82 (2.06) | 2.08 (1.44) | 1.12 (0.39 to 1.84) | |
| Triglycerides (mmol/L) | 1.61 (0.75) | 1.57 (0.73) | 1.54 (0.91) | 0.973 | 0.09 (-0.18 to 0.35) |
| Total Cholesterol (mmol/L) | 4.93 (1.34) | 4.93 (1.24) | 5.30 (0.95) | 0.527 | -0.33 (-0.70 to 0.04) |
| HDL (mmol/L) | 1.30 (0.30) | 1.22 (0.34) | 1.38 (0.29) | 0.223 | -0.28 (-0.37 to -0.19) |
| LDL (mmol/L) | 2.88 (1.10) | 2.96 (1.03) | 3.27 (0.87) | 0.464 | -0.41 (-0.72 to -0.09) |
| FFA (umol/L) | 531.83 (196.93) | 439.92 (188.65) | 378.49 (156.79) | 0.89(-55.62 to 57.39) | |
Data presented as mean (SD). IQR interquartile range, ES effect size, CI confidence interval, M male, F female, MAFLD metabolic dysfunction-associated fatty liver disease, Y yes, N no, BMI body mass index, LF% liver fat percentage, SBP systolic blood pressure, DBP diastolic blood pressure, AST aspartate aminotransferase, ALT alanine aminotransferase, CRP high-sensitivity C-reactive protein, FBG fasting blood glucose, HOMA-IR homeostatic model assessment of insulin resistance, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, FFA free fatty acids, VO Peak oxygen consumption. aHOMA-IR and insulin measures reported for 37 participants with normal glucose tolerance and 29 participants with T2D as 6 participants with T2D were undergoing exogenous insulin therapy. bsignificant difference between lowest and highest fitness; csignificant difference between lowest fitness and IQR
Fig. 1Differences in liver fat content and insulin resistance between CRF quartiles. Data presented as mean (SD). ES, effect size; CI, confidence interval; LF%, liver fat percentage; HOMA-IR, homeostatic model of insulin resistance; IQR, interquartile range. Brackets indicate significant difference